WO1998042392A1 - Adsorbant destine a eliminer le virus de l'hepatite c, adsorbeur et methode d'adsorption - Google Patents
Adsorbant destine a eliminer le virus de l'hepatite c, adsorbeur et methode d'adsorption Download PDFInfo
- Publication number
- WO1998042392A1 WO1998042392A1 PCT/JP1998/001317 JP9801317W WO9842392A1 WO 1998042392 A1 WO1998042392 A1 WO 1998042392A1 JP 9801317 W JP9801317 W JP 9801317W WO 9842392 A1 WO9842392 A1 WO 9842392A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- hepatitis
- adsorbent
- immunoglobulin
- protein
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 99
- 239000003463 adsorbent Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 108060003951 Immunoglobulin Proteins 0.000 claims description 36
- 102000018358 immunoglobulin Human genes 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 23
- 210000001124 body fluid Anatomy 0.000 claims description 18
- 239000011148 porous material Substances 0.000 claims description 18
- 239000010839 body fluid Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 11
- 102000028557 immunoglobulin binding proteins Human genes 0.000 claims description 9
- 108091009323 immunoglobulin binding proteins Proteins 0.000 claims description 9
- 101710120037 Toxin CcdB Proteins 0.000 claims description 8
- 230000003100 immobilizing effect Effects 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 108010055837 phosphocarrier protein HPr Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 abstract description 8
- 108010050904 Interferons Proteins 0.000 abstract description 8
- 229940079322 interferon Drugs 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000000499 gel Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 239000004593 Epoxy Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- -1 plasma Substances 0.000 description 9
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 208000005176 Hepatitis C Diseases 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000005484 gravity Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 2
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 2
- GWTLRDMPMJCNMH-WHFBIAKZSA-N Asp-Asn-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GWTLRDMPMJCNMH-WHFBIAKZSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 2
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 description 2
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
- JONPRIHUYSPIMA-UWJYBYFXSA-N Tyr-Ala-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JONPRIHUYSPIMA-UWJYBYFXSA-N 0.000 description 2
- NRFTYDWKWGJLAR-MELADBBJSA-N Tyr-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O NRFTYDWKWGJLAR-MELADBBJSA-N 0.000 description 2
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 2
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 2
- OEVFFOBAXHBXKM-HSHDSVGOSA-N Val-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](C(C)C)N)O OEVFFOBAXHBXKM-HSHDSVGOSA-N 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 102000034238 globular proteins Human genes 0.000 description 2
- 108091005896 globular proteins Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000012052 hydrophilic carrier Substances 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 1
- IZKGGDFLLNVXNZ-KRWDZBQOSA-N (2s)-5-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 IZKGGDFLLNVXNZ-KRWDZBQOSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 102000028555 IgG binding proteins Human genes 0.000 description 1
- 108091009325 IgG binding proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine group Chemical group [*].[H]OC(=O)[C@@]([H])(N([H])[H])C([H])([H])SSC([C@@](C(=O)O[H])(N([H])[H])[H])([H])[H] LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- YIBOAHAOAWACDK-QEJZJMRPSA-N Lys-Ala-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YIBOAHAOAWACDK-QEJZJMRPSA-N 0.000 description 1
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 1
- HAQLBBVZAGMESV-IHRRRGAJSA-N Met-Lys-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O HAQLBBVZAGMESV-IHRRRGAJSA-N 0.000 description 1
- ZSHJENHLFBWELN-UHFFFAOYSA-N Met-Thr-Thr-Tyr Chemical compound CSCCC(N)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 ZSHJENHLFBWELN-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- ACOGMWBDRJJKNB-UHFFFAOYSA-N acetic acid;ethene Chemical compound C=C.CC(O)=O ACOGMWBDRJJKNB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 108010038679 colligin Proteins 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
- 229950010248 loretin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- WCNLCIJMFAJCPX-UHFFFAOYSA-N pethidine hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 WCNLCIJMFAJCPX-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3255—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7509—General characteristics of the apparatus with filters for virus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/58—Use in a single column
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
Definitions
- the present invention provides an adsorbent for removing hepatitis C virus, which promotes the treatment of hepatitis C by selectively adsorbing and removing hepatitis C virus present in body fluids such as blood and plasma. And a method for adsorbing and removing hepatitis C virus.
- hepatitis C was found to be mostly non-A non-B hepatitis in the past, and hepatitis C virus carriers are currently about 200,000 in Japan. It has been estimated that 1.4 million people have chronic hepatitis and 300,000 have cirrhosis. (Shiro Iino: Practice of gastrointestinal practice 2. Hepatitis C, 11–17 (1993 ”).
- hepatitis C is an intractable disease that progresses to cirrhosis and hepatocellular carcinoma.
- hepatitis C has mainly been rest therapy, diet therapy, and drug therapy centered on liver protectants and herbal medicines.However, these treatments cannot eliminate the hepatitis virus, and there are no cures for hepatitis. Very few, to reduce the progression of chronic liver disease by reducing liver necrosis The focus was on it. Therefore, as described above, many patients eventually have an unfortunate outcome of cirrhosis or hepatocellular carcinoma as described above.
- the effectiveness of this treatment depends on the hepatitis C virus gene transfer type, the amount of virus in the blood, and the degree of progression of liver lesions. Among them, the amount of virus in the blood is the most important factor. Has become. For example, if the amount of virus in 1 mL of a patient's blood is less than 100,000 copies, about 80% of the patient's internal virus can be completely eliminated and cured by interferon administration, whereas 100% can be cured. In the case of 10,000 copies or more, only 9% of the cases were cured (Fumio Imazeki et al .; Japanese clinical study, 53, 107 (199)
- the present inventors also examined the presence of virus granule in blood. It was also found that the mode of presence was also an important factor in the efficacy of intervening therapy. In other words, hepatitis C virus particles are reported to be classified into highly infectious, light particles and low infectious, heavy particles according to their buoyant density in blood.Virus particles with different densities As a result of a study focusing on the relationship between disease and pathology, and interferon treatment, if the ratio of light virus particles to heavy virus particles in the patient's blood was 10: 1, 75% of patients were treated with interferon. Healing was observed in only one to ten patients, whereas only 13% of the patients were cured.
- the current interferon therapy has a higher therapeutic effect as the amount of virus in the blood is lower and the amount of immunocomplex-type virus bound to the immunoglobulin is lower, but the virus in the blood is less virulent. It became clear that the healing effect was significantly reduced as the amount was higher and the amount of the immune complex virus was higher.
- the present invention can efficiently and selectively adsorb and remove hepatitis C virus, particularly immunocomplex hepatitis C virus, in patient blood in order to further enhance the therapeutic effect of interferon. It is another object of the present invention to provide an adsorbent for removing hepatitis C virus, which is excellent in safety, and to provide an adsorption apparatus using the adsorbent and a method for adsorbing and removing hepatitis C virus.
- the present inventors have found that, by binding various compounds to a water-insoluble carrier and bringing them into contact with a patient's blood, they have high adsorption activity against hepatitis C virus, Intensive research has been conducted to obtain compounds that do not have adsorption activity for proteins.
- an adsorbent in which a compound capable of adsorbing hepatitis C virus, in particular, a compound having binding activity to immunoglobulin and / or immune complex, is immobilized on a water-insoluble carrier, and a remarkably excellent C-type liver They found that they had the ability to adsorb flame viruses, and completed the present invention.
- the present invention is an adsorbent for removing hepatitis C virus obtained by immobilizing a compound capable of adsorbing hepatitis C virus on a water-insoluble carrier.
- FIG. 1 is a diagram showing the relationship between flow rate and pressure loss when a glass cylindrical column is filled with various water-insoluble carriers.
- the vertical axis represents flow rate (for cmZ), and the horizontal axis represents pressure loss (kg / cm 2 ).
- FIG. 2 is a schematic sectional view showing the device for adsorbing hepatitis C virus of the present invention.
- FIG. 3 is a diagram showing pUCNTMK3P47 vector.
- the adsorbent for removing hepatitis C virus of the present invention is obtained by immobilizing a compound having an adsorbing ability on hepatitis C virus on a water-insoluble carrier.
- the compound having the ability to adsorb to the hepatitis C virus is not particularly limited as long as it is a compound having an activity to adsorb to the hepatitis C virus.
- more preferred compounds are immunoglobulin and Z or immunoglobulin complex in adsorbing and removing hepatitis C virus.
- the body joins It is a compound that can preferentially and efficiently adsorb and remove hepatitis c virus.
- the compound having binding activity to the immunoglobulin and Z or the immunoglobulin complex is more preferably an immunoglobulin-binding protein.
- immunoglobulin-binding protein examples include, for example, protein A, protein G, protein H, protein L, protein M, rheumatoid factor, and the like.
- the compound having a binding activity to the immunoglobulin and / or the immunoglobulin complex is more preferably an anti-immunoglobulin antibody.
- the compound having the ability to adsorb hepatitis C virus is more preferably the immunoglobulin-binding protein and a part of the immunoglobulin antibody, and the immunoglobulin and / or immunoglobulin complex. Or a protein fragment or peptide containing a binding site for or a derivative thereof.
- One preferred form of the water-insoluble carrier is porous.
- the average pore size of the porous water-insoluble carrier is preferably from 10 to 150 nm.
- One preferred form of the water-insoluble carrier is that it is substantially non-porous.
- the water-insoluble carrier is preferably hydrophilic.
- the adsorbent for removing hepatitis C virus of the present invention can be used to adsorb and remove hepatitis C virus present in blood, plasma, and other body fluids.
- the adsorbent for removing hepatitis C virus of the present invention can be used for adsorbing and removing immunocomplex virus present in blood, plasma, and other body fluids.
- the hepatitis C virus adsorption device of the present invention includes the adsorbent for removing hepatitis C virus described above in a container having a liquid inlet and an outlet, and the hepatitis C virus described above. It is characterized in that a means for preventing the adsorbent for removal from flowing out of the container is provided.
- the hepatitis C virus adsorption method of the present invention includes a step of contacting the adsorbent for removing hepatitis C virus described above with a liquid containing hepatitis C virus. is there.
- the liquid containing the hepatitis C virus includes, for example, blood, plasma, and other body fluids.
- the present invention is not limited to the following description.
- the compound having the ability to adsorb hepatitis C virus used in the present invention refers to a compound having the ability to adsorb hepatitis C virus substantially, and is not limited to a specific compound, but is preferably
- the substance is preferably a substance that specifically binds to the heavy or light chain portion in the immunoglobulin and / or immunoglobulin complex.
- Examples of the substance that specifically binds to a heavy chain portion or a light chain portion in the immunoglobulin and / or immunoglobulin complex include, for example, a substance having a binding activity to an Fc region in a heavy chain of immunoglobulin G.
- immunoglobulin-binding proteins such as protein A, protein G, protein H, protein M, rheumatoid factor, protein L, and protein L having binding activity to light chains (L. Bj 0 rck: J. Immuno 1., 140, 1194 (1988), H. Gomi, et al .: J. Immunol., 144.4046 (1990), Naoyuki Doi: Immunology, 23, 896, (1991)) (4) Anti-immunoglobulin antibodies and the like.
- Fab, F (ab) 2 single chain of rheumatoid factor or anti-immunoglobulin antibody Fv polypeptides and the like can also be mentioned as typical examples.
- the water-insoluble carrier used in the present invention is not particularly limited.
- examples thereof include inorganic carriers such as glass beads and silica gel, synthetic polymers such as cross-linked polyvinyl alcohol, cross-linked polyacrylate, cross-linked polyacrylamide, and cross-linked polystyrene, and crystalline polymers.
- Organic carriers composed of polysaccharides such as cell opening, crosslinked cellulose, cross-linked agarose, cross-linked dextran, etc., and organic-organic and organic-inorganic composite carriers obtained by a combination thereof can also be mentioned.
- hydrophilic carriers are preferred because they have relatively low nonspecific adsorption and have good adsorption selectivity for hepatitis C virus.
- the hydrophilic carrier as used herein means a compound having a contact angle with water of 60 degrees or less when a compound constituting the carrier is formed into a plate.
- Such carriers are not particularly limited, and include, for example, polysaccharides such as cellulose, chitosan, cepharose, dextran, polyvinyl alcohol, saponified ethylene monoacetate vinyl copolymer, polyacrylamide, polyacrylic acid, Carriers made of polymethacrylic acid, polymethyl methacrylate, polyacrylic acid-grafted polyethylene, polyacrylamide-grafted polyethylene, glass and the like can be mentioned.
- polysaccharides such as cellulose, chitosan, cepharose, dextran, polyvinyl alcohol, saponified ethylene monoacetate vinyl copolymer
- polyacrylamide polyacrylic acid
- Carriers made of polymethacrylic acid, polymethyl methacrylate, polyacrylic acid-grafted polyethylene, polyacrylamide-grafted polyethylene, glass and the like can be mentioned.
- a carrier having an OH group is excellent in adsorption performance and selectivity, and a porous cellulose gel has the following excellent points (1) to (4). It is one of the most preferred as the water-insoluble carrier of the present invention.
- the gel is composed of cellulose, it is hydrophilic, has a large number of hydroxyl groups that can be used for ligand binding, and has low non-specific adsorption.
- the above water-insoluble carriers may be used alone or in combination of two or more. They may be used in combination.
- the water-insoluble carrier used in the present invention preferably has a large surface area in view of the intended purpose and method of the adsorbent for removing hepatitis C virus of the present invention, and has a large number of pores of an appropriate size. It is preferably porous.
- the average pore size of the porous water-insoluble carrier is preferably from 10 to 150 nm.
- the hepatitis C virus is a particle having a diameter of 50 to 55 nm.
- the pore size distribution of the pores is determined by the diameter of the virus particles. It is preferable that the carrier be widely distributed on the side of the larger pore diameter. However, if it is too large, the strength of the carrier decreases and the surface area decreases.
- a more preferred average pore size is from 50 to 125 nm.
- virus can be adsorbed even on a substantially non-porous carrier having no pores.
- useful components for living organisms such as proteins in body fluids (blood, plasma, serum, etc.) cannot enter the pores, and thus have the advantage that they are hardly adsorbed. is there.
- substantially non-porous means that a porous carrier having pores having a very small pore diameter (for example, less than 10 nm) even if it is porous is included.
- the pore volume is 20% or more, and the specific surface area is 3%. It is preferably at least m 2 Z g.
- the form of the water-insoluble carrier is not particularly limited, and may be, for example, beads, fibrils, membranes (including hollow fibers), and the like. Particularly preferably used.
- the average particle size of the above bead-shaped carrier is preferably in the range of 10 to 2,500 im, but preferably in the range of 25 to 800 m.
- the representative examples of the functional groups are not particularly limited, and include, for example, a hydroxyl group, an amino group, an aldehyde group, a carboxyl group, a thiol group, a silanol group, an amide group, an epoxy group, a succinilimide group, and an acid anhydride. And the like.
- a water-insoluble carrier either a hard carrier or a soft carrier can be used.However, in order to use the water-insoluble carrier as an adsorbent for extracorporeal circulation treatment, clogging occurs when the column is filled and passed through. It is important that the water-insoluble carrier is a rigid carrier, since sufficient mechanical strength is required for that purpose.
- the term "hard carrier” refers to, for example, in the case of a granular gel, the gel is uniformly filled in a glass cylindrical column (inner diameter 9 mm, column length 150 mm) under the following conditions, and the aqueous fluid pressure loss at the time of flow ([Delta] [rho]) and flow rate relationship, refers to those in the straight-line relationship to 0. 3 kg / cm z.
- agarose gel Bioge 1—A 5 m, particle size: ⁇ io—Rad
- a cylindrical glass column 9 mm inside diameter, column length 150 mm
- a filter with a pore size of 15 zm at both ends.
- 50-1000 mesh, vinyl polymer gel Toyopearl HW-65, manufactured by Toyo Soda Kogyo Co., Ltd., particle size 50-10000 // m
- cell mouth gel Choso Corporation
- Cellulofine GC—700 m, particle size 45-105 m) was uniformly filled, water was flowed by a peristaltic pump, and the relationship between flow rate and pressure loss ( ⁇ ) was determined. ( Figure 1 ) .
- the vertical axis plots the flow velocity (for cmZ), and the horizontal axis plots the pressure loss (kgZcm 2 ).
- ⁇ indicates Toyopearl HW-65
- ⁇ indicates Cell mouth fine GC-700 m
- black colored ⁇ indicates Bioge I-A 5 m.
- the flow rate of Toyopearl Toyopearl HW-65 and Cell mouth Fine GC-700m increased almost in proportion to the increase in pressure, while Biogel-A5m caused consolidation and increased pressure. It was found that increasing the flow rate did not increase the flow rate.
- the adsorption efficiency is improved by reducing the steric hindrance of the protein or the peptide, and furthermore, the nonspecific adsorption is suppressed. It is more preferable to immobilize via a hydrophilic spacer.
- hydrophilic spacer for example, it is preferable to use a polyalkylene oxide derivative in which both terminals are substituted with a carboxyl group, an amino group, an aldehyde group, an epoxy group, or the like.
- Immunoglobulin and immunoglobulin or immunoglobulin complex introduced into the water-insoluble carrier The method of immobilizing a compound having a binding activity to the body and an organic compound used as a spacer is not particularly limited, but an epoxy generally used when immobilizing a protein or a peptide to a carrier is used. Immobilization methods such as a reaction, a nick base reaction, a condensation reaction using a carbodiimide reagent, an active ester reaction, a carrier crosslinking reaction using a glutaraldehyde reagent, and the like can be given.
- the adsorbent for removing hepatitis C virus of the present invention is an adsorbent that can be used for body circulation treatment and blood purification
- the protein may be used during sterilization or treatment of the adsorbent. More preferably, an immobilization method that does not easily desorb from the water-insoluble carrier is applied, and examples thereof include the following methods.
- adsorbing and removing hepatitis C virus in body fluids by bringing a carrier, on which a compound capable of adsorbing hepatitis C virus, is immobilized into contact with body fluids such as blood, plasma, and serum.
- body fluids such as blood, plasma, and serum.
- the adsorbent for removing hepatitis C virus of the present invention is suitable for this method.
- a device for adsorbing hepatitis C virus of the present invention using an adsorbent for removing hepatitis C virus, which adsorbs hepatitis C virus, will be described based on a schematic cross-sectional view thereof.
- the container 7 shown in FIG. 2 has a liquid inlet or outlet 1, a liquid outlet or ⁇ inlet 2, the adsorbent for hepatitis C virus removal 3 of the present invention, and liquids and components contained in the liquid. However, it has adsorbent outflow prevention means 4 and 5, which cannot pass through the adsorbent for removing hepatitis C virus, and column 6.
- This container is not particularly limited, but preferably, for example, the capacity 2
- a cylindrical container having a diameter of about 0 to 40 OmL and a diameter of about 2 to 10 cm is used.
- L-alanine residue Asp
- L-aspartic acid residue Asn
- L-asparagine residue Cys
- L-cystine residue Gin
- L-glutamine residue Glu
- L-glutamic acid Residue Gly; L-glycine residue, lie; L-isoleucine residue, Leu; L-mouth isine residue, Lys; L- lysine residue, Phe; L- phenylalanine residue, Thr; L- Threonine residue, Trp; L—tryptophan residue, Tyr; L—Thai mouth syn residue, Val; L—Valin residue.
- N-terminus amino terminus
- C-terminus carboxyl terminus
- GC L 2000 m (manufactured by Chisso, 30000 molecular weight exclusion limit of globular protein) Water was added to 9 OmL to bring the total volume to 180 mL. Then, 60 mL of 2M sodium hydroxide was added thereto, and the mixture was adjusted to 40. To this, 21 mL of epichlorohydrin was added and reacted at 40 ° C. for 1 hour with stirring. After the completion of the reaction, the resultant was sufficiently washed with water to obtain an epoxy-activated cellulose gel.
- Protein A (manufactured by Sigma) is dissolved in 0.5 mL of 0.05 M borate buffer (pH 10.0), and added with an aqueous solution of 0.01 N sodium hydroxide to adjust pH 1 It was readjusted to 0 and the total amount was adjusted to 1.
- OmL Protein A solution
- PBS 10 mM phosphate buffer containing 150 mM sodium chloride
- Amino acids include Fmoc-L-Ala, Fmoc-L-Asn (Trt), Fmoc-L-Asp (OtBu), Fmoc-L-Cys (Trt), Fmoc_L-Gln (Trt), Fmo c-I: L—Glu (OtBu), Fmo c—L—Gly, Fmo c_L—Ile, Fmo c—L—Leu, Fmo c-L—LysCBoc), Fmo c—L—Phe, Fmo c—L — Thr (tBu), F moc— L— Trp, F moc-L -TyrCtBu).
- Trt, 0tBu, Boc, and tBu represent a trityl group, a tert-butyl ester, a tert-butyloxycarbonyl group, and a tert-butyl group, respectively.
- the obtained support is sequentially washed with tert-amyl alcohol, acetic acid and getyl ether on a 3G-3 pore glass filter, and then dried under vacuum. Thus, a dry support was obtained.
- 20 mL of trifluoroacetic acid (TFA) was added to 1 g of the obtained support.
- 2-Ethanedithiol 260 / L and anisol 780 uL were added, and the mixture was stirred at room temperature for 5 hours.
- this mixture was separated from the support by a 3 G-3 pore glass filter, and the filtrate was concentrated under reduced pressure at a temperature of 35 ° C.
- Preliminarily cooled anhydrous getyl ether was added thereto until no precipitate appeared, followed by stirring and then centrifugation to collect the precipitated crude peptide. Further, the crude peptide was washed several times with anhydrous getyl ether, and then dried under reduced pressure to obtain a target crude purified peptide.
- the above-mentioned crude peptide was dissolved in 0.1% TFA and filtered through a 0.2 m membrane filter, and the obtained filtrate was subjected to high performance liquid chromatography.
- HPLC a Mode 1LC-10A system (manufactured by Shimadzu Corporation) was used, and as the column, a reverse-phase B0ndaspHERECI8 (manufactured by Nippon Millipore Waters) was used.
- a 0.1% aqueous solution of TFA was used as the mobile phase A, and 80% (VZV) acetonitrile / water containing 0.1% TFA was used as the mobile phase B. Eluted.
- the corresponding fraction of the obtained chromatographic peak was collected. The fractionation was repeated several times, and this was freeze-dried to obtain a purified peptide.
- the obtained peptide was analyzed by gas-phase protein sequencer type 479 (manufactured by Applied Biosystems) and amino acid analysis using a Hitachi custom exchange resin, and the amino acid described in SEQ ID NO: 1 in the sequence listing was obtained. It was confirmed that a peptide having an acid sequence was obtained.
- the adsorbent was produced as follows by immobilizing the above peptide on porous sepharose.
- Thiopropyl Sepharose 6B (Pharmacia LKB) was used as Sepharose.
- 50 ml of distilled water was added to 50 mg of thiopropyl sepharose 6B, and the mixture was left at room temperature for 15 minutes to swell the resin. Then, distilled water was removed and replaced with 0.1 M Tris-HCl (pH 7.5) coupling buffer containing 0.5 M NaCl.
- the obtained peptide-immobilized adsorbent was subjected to suction filtration, and the peptide content in the filtrate was quantified by an absolute calibration curve method using HPLC, whereby the immobilization rate of the peptide on the carrier was determined.
- This peptide-immobilized adsorbent was sufficiently washed with 10 mM phosphate buffer (pH 7.2) containing 150 mM NaC1, filtered by suction, and washed with 1 mL of carrier. 3.
- Sepharose 6 BC 3 Ppt with 6 mg of the peptide immobilized thereon was obtained.
- the DNA encoding the MK3P47 peptide which has the amino acid sequence described in SEQ ID NO: 2 in the following sequence listing, was added to the pUCNT vector (Japanese Patent Application Laid-Open No. 4-212926). It was designed so that ligation could be performed by using restriction enzyme sites of Nde I and 3 'and Hind III, respectively.
- the synthesized DNA sequence is shown in SEQ ID NO: 3 in the sequence listing.
- PUC NT vector obtained by digesting DNA having the above sequence by digestion with restriction enzymes Nde I and Hind II1 (Takara Shuzo Co., Ltd.), and DNA Ligatione from Takara Shuzo Co., Ltd.
- KitV er.2 The kit was ligated using KitV er.2 according to the procedure manual to prepare a pUCNTMK3P47 vector (FIG. 3).
- This PUCNTMK3P47 vector DNA was introduced into Escherichia coli HB101 strain (manufactured by ivivitrogen) by a known method, and transformants were selected using the resistance to the antibiotic ampicillin as an index.
- Plasmid DNA was extracted from the transformant by a conventional method, and the gene sequence was analyzed to confirm that the pUCNTMK3P47 vector had a DNA sequence as designed.
- the transformants were then incubated in 6 L of L-broth (5 g ZL NaCl, 10 g / L Bactotrypsin, 5 g / L yeast extract). At C 2 0 After culturing with shaking for a period of time, the cells were collected by centrifugation (600 rpm at 4 ° C. for 20 minutes using a Hitachi RPR 9-2 rotor).
- the precipitate obtained here was suspended in 300 mL of TE buffer (20 mM Tris-HC1, 1 mM EDTA: pH 7.5), and sonicated (BRANS ON). The supernatant was collected by centrifugation (1500 rpm, 4 min at 4 ° C using a Hitachi RPR 16 rotor) for 20 min. did.
- the obtained supernatant was heat-treated at 70 ° C for 10 minutes, and then centrifuged (using a Hitachi RPR16 rotor at 4 ° C at 1500 rpm for 20 minutes). ), 30 O mL of the supernatant was recovered. Using a high performance liquid chromatograph (column: Watersz BONDAS PHERE 5 ⁇ . C18300A19.0Ox150mm) from this supernatant, flow 40ml of acetonitrile solution at a flow rate of 5m1.
- Peptide MP47C having the amino acid sequence described in SEQ ID NO: 4 in the sequence listing was produced.
- DNA (DNA encoding MP47C) having the sequence shown in SEQ ID NO: 5 in the sequence listing was designed and synthesized to be ligated to one pUCNT vector in the same manner as in Example 4. .
- DNA having the above sequence was introduced into the pUCNT vector in the same manner as in Example 4 to prepare a pUCNTMP47C vector.
- Sephacry 1 S 100 000 (Pharmacia LKB), a cellulosic porous hard gel with a pore size of 400 nm, was added to 90 mL of water to bring the total volume to 180 mL, and then 2M hydroxylated. 6 OmL of sodium was added to adjust the temperature to 40 ° C. To this, 2 l mL of epipic hydrin was added, and reacted at 40 ° C. for 1 hour with stirring. After the completion of the reaction, the resultant was sufficiently washed with water to obtain an epoxy-activated sephacryl gel.
- MP47C was immobilized in exactly the same manner as in Example 1 except that 4 mg of protein A was changed to 10 mg of MP47C, and the epoxy activated gel was changed to an epoxy activated sephacryl gel. 100-MP-47C (7 mg / mL) was obtained.
- a non-porous carrier (Bac), which is a prototype of a cellulose-based hard gel with a molecular weight of exclusion of spherical proteins of 30,000 or less, to make the total volume 180 mL, and then 2 M sodium hydroxide 6 0 mL was added to bring the temperature to 40 ° C.
- Example 7 MP with MP47C immobilized in exactly the same manner except that 4 mg of protein A of Example 1 was changed to 30 mg of MP47C and the epoxy activated gel was changed to Bac. 47 C (20 mg / mL) was obtained.
- Example 7 MP with MP47C immobilized in exactly the same manner except that 4 mg of protein A of Example 1 was changed to 30 mg of MP47C and the epoxy activated gel was changed to Bac. 47 C (20 mg / mL) was obtained.
- An anti-human IgG (Fb) antibody (manufactured by Binding Site, Inc.) was digested into papain by digesting with 1 mL of the cutting buffer (PIECE, ImmunoPureFab).
- block buffer one (p H 8. 3, 0. 2 M of glycine, 0. 5 M sodium chloride in, N aHC0 3 of 0. 1 M) was added 2 at room temperature Reacted for hours.
- block buffer pH 8.0, 0.5 M sodium chloride, 0.1 M tris-hydrochloric acid buffer
- HCV RNA manufactured by Nippon Roche Co., Ltd., Amplicon HCV monitor.
- the hepatitis C virus adsorption rate (%) was calculated by the following equation.
- Adsorption rate (:%) [(Vr—Vt) Vr] X100
- V r virus concentration in the control solution
- V t virus concentration in the supernatant of the adsorption experiment
- the HCV suspension obtained in the adsorption experiment and the HCV suspension treated in the same manner with physiological saline instead of the adsorbent were mixed with anti-LDL antibody and anti-IgG antibody and reacted at 4 ° C for 16 hours.
- HCV RNA human immunoglobulin C virus
- HCV RNA ratio low specific gravity HCVZ high specific gravity HCV
- the ability to selectively adsorb and remove hepatitis C virus present in body fluids, and the ratio of Z or high specific gravity HCV virus to low specific gravity HCV virus can be provided. Further, by using a body fluid treatment device filled with the above-mentioned adsorbent, it is possible to selectively remove hepatitis C virus from non-treated solutions such as blood, plasma, and serum.
- Sequence type nucleic acid
- Sequence type nucleic acid
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/380,644 US6600014B2 (en) | 1997-03-25 | 1998-03-25 | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method |
KR1019997008754A KR20010005686A (ko) | 1997-03-25 | 1998-03-25 | C형 간염 바이러스 제거용 흡착재, 흡착장치 및 흡착방법 |
CA002284619A CA2284619A1 (en) | 1997-03-25 | 1998-03-25 | Absorbent for eliminating hepatitis c virus, absorber, and absorption method |
EP98910991A EP0972530A4 (en) | 1997-03-25 | 1998-03-25 | ADSORBENT FOR ELIMINATION OF HEPATITIS C VIRUS, ADSORBER AND METHOD OF ADSORPTION |
US10/458,297 US7056507B2 (en) | 1997-03-25 | 2003-06-11 | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7148397 | 1997-03-25 | ||
JP9/71483 | 1997-03-25 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/380,644 A-371-Of-International US6600014B2 (en) | 1997-03-25 | 1998-03-25 | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method |
US09380644 A-371-Of-International | 1998-03-25 | ||
US10/458,297 Continuation US7056507B2 (en) | 1997-03-25 | 2003-06-11 | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998042392A1 true WO1998042392A1 (fr) | 1998-10-01 |
Family
ID=13461947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/001317 WO1998042392A1 (fr) | 1997-03-25 | 1998-03-25 | Adsorbant destine a eliminer le virus de l'hepatite c, adsorbeur et methode d'adsorption |
Country Status (8)
Country | Link |
---|---|
US (2) | US6600014B2 (ja) |
EP (1) | EP0972530A4 (ja) |
KR (2) | KR20010005686A (ja) |
CN (1) | CN1286535C (ja) |
CA (1) | CA2284619A1 (ja) |
ID (1) | ID22902A (ja) |
TW (1) | TW514537B (ja) |
WO (1) | WO1998042392A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003088381A (ja) * | 2001-09-18 | 2003-03-25 | Kanegafuchi Chem Ind Co Ltd | 新規ペプチド、生産方法、新規吸着体、吸着器および吸着方法 |
WO2008016221A1 (en) | 2006-06-27 | 2008-02-07 | Korea Research Institute Of Bioscience And Biotechnology | Cysteine-tagged staphylococcal protein g variant |
CN101185878B (zh) * | 2006-11-17 | 2010-05-26 | 广州康盛生物科技有限公司 | 一种用于去除致病抗体及其复合物的蛋白a免疫吸附材料及其合成方法和应用 |
CN103933947A (zh) * | 2014-04-10 | 2014-07-23 | 大连理工大学 | 用于清除类风湿因子的血液净化材料及其制备方法 |
US20180039170A1 (en) * | 2015-02-27 | 2018-02-08 | Canon Kabushiki Kaisha | Nanonimprint liquid material, method for manufacturing nanoimprint liquid material, method for manufacturing cured product pattern, method for manufacturing optical component, and method for manufacturing circuit board |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7682793B2 (en) * | 2001-08-01 | 2010-03-23 | Chauhan Anil K | Immune complexes |
CA2464351A1 (en) * | 2001-10-16 | 2003-04-24 | Asahi Medical Co., Ltd. | Method for selectively removing virus and leukocytes, removing material and removing apparatus |
JP2003235959A (ja) * | 2002-02-14 | 2003-08-26 | Nippon Koutai Kenkyusho:Kk | C型肝炎ウイルスの除去・減量方法 |
JP2007529747A (ja) * | 2004-03-17 | 2007-10-25 | ユニバーシティ オブ ハワイ | センサ構造物及び検出方法 |
EP1763575A4 (en) * | 2004-04-27 | 2009-09-23 | Baxter Int | REACTOR SYSTEM WITH AGITATION RESERVOIR |
EP1790365B1 (en) * | 2004-07-23 | 2015-11-18 | Kaneka Corporation | Direct hemoperfusion adsorber packed with adsorbent having water-insoluble microparticles removed therefrom, and method of obtaining direct hemoperfusion adsorber packed with adsorbent having water-insoluble microparticles removed therefrom |
MX2008007716A (es) | 2005-12-13 | 2008-09-26 | Exthera Ab | Metodo para eliminar extra corporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria. |
CN101069751B (zh) * | 2006-05-10 | 2011-02-09 | 广州康盛生物科技有限公司 | 一种蛋白a免疫吸附材料及其制备方法 |
US9604196B2 (en) | 2006-11-20 | 2017-03-28 | Cytosorbent, Inc. | Size-selective hemocompatible polymer system |
US7875182B2 (en) * | 2006-11-20 | 2011-01-25 | Cytosorbents, Inc. | Size-selective hemoperfusion polymeric adsorbents |
US8211310B2 (en) | 2006-11-20 | 2012-07-03 | Cytosorbents, Inc. | Size-selective polymer system |
WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
ES2628513T3 (es) * | 2009-10-08 | 2017-08-03 | Otsuka Pharmaceutical Co., Ltd. | Un filtro de perfusión sanguínea de inmunoactivación para el tratamiento de tumores malignos |
CN106178161B (zh) | 2009-12-01 | 2020-12-22 | 艾克塞拉医疗公司 | 使用固定于表面的多糖从血液中去除细胞因子的方法 |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
US20120219633A1 (en) * | 2011-02-28 | 2012-08-30 | Pall Corporation | Removal of immunoglobulins and leukocytes from biological fluids |
EP2861273B1 (en) | 2012-06-13 | 2017-08-23 | ExThera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
EP3013445B1 (en) | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
CN103394331B (zh) * | 2013-07-25 | 2015-02-11 | 武汉大学 | 一种丙型肝炎病毒吸附剂及其制备方法与应用 |
WO2015069942A1 (en) | 2013-11-08 | 2015-05-14 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
BR112016024569B1 (pt) | 2014-04-24 | 2023-01-03 | Exthera Medical Corporation | Método ex vivo para remover bactérias de uma amostra retirada de um indivíduo que é suspeito de estar infectado com a mesma |
EP3197342B1 (en) | 2014-09-22 | 2020-08-05 | ExThera Medical Corporation | Wearable hemoperfusion device |
CN104801278A (zh) * | 2015-03-29 | 2015-07-29 | 武汉瑞法医疗器械有限公司 | 艾滋病毒亲和吸附剂的制备方法 |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
EP3422943A4 (en) | 2016-03-02 | 2019-10-16 | ExThera Medical Corporation | METHOD OF TREATING DRUG ENTRIES |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0447984A1 (en) * | 1990-03-20 | 1991-09-25 | Abbott Laboratories | Hyperimmune globulin against hepatitis C virus and method for making same |
JPH0640926A (ja) * | 1992-07-24 | 1994-02-15 | Chemo Sero Therapeut Res Inst | C型肝炎ウイルスの除去方法 |
RU2095815C1 (ru) * | 1994-12-22 | 1997-11-10 | Леонид Николаевич Падюков | Способ получения иммуносорбента для диагностики вирусного гепатита с |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59193135A (ja) | 1983-04-18 | 1984-11-01 | Kanegafuchi Chem Ind Co Ltd | 吸着体 |
CA1221307A (en) * | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
US5037649A (en) * | 1985-01-11 | 1991-08-06 | Imre Corporation | Method for treatment of HIV-infected patients |
US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
GB8902770D0 (en) | 1989-02-08 | 1989-03-30 | Bioprocessing Ltd | Improvements in or relating to supports for immunoaffinity separations |
DK0752425T3 (da) | 1995-06-21 | 2000-04-10 | Tecnogen Scpa | Peptidligander for den konstante region på immunoglobuliner |
JPH093350A (ja) * | 1995-06-22 | 1997-01-07 | Daisutaa Japan Kk | 青色系分散染料混合物 |
JP3737516B2 (ja) * | 1995-06-26 | 2006-01-18 | パーセプティブ バイオシステムズ,インコーポレーテッド | 高速自動化連続流、多次元分子選別および分析 |
JPH0933530A (ja) * | 1995-07-19 | 1997-02-07 | B M L:Kk | ウイルスの定量方法 |
EP0882463B1 (en) * | 1996-01-25 | 2005-06-08 | Kaneka Corporation | Adsorbent for immunoglobulins and complexes thereof and adsorption device |
US5846735A (en) * | 1996-04-18 | 1998-12-08 | University Of Iowa Research Foundation | Hepatitis C virus Fc-binding function |
-
1998
- 1998-03-25 WO PCT/JP1998/001317 patent/WO1998042392A1/ja not_active Application Discontinuation
- 1998-03-25 US US09/380,644 patent/US6600014B2/en not_active Expired - Fee Related
- 1998-03-25 KR KR1019997008754A patent/KR20010005686A/ko active Application Filing
- 1998-03-25 KR KR1020067002145A patent/KR20060015703A/ko not_active Application Discontinuation
- 1998-03-25 EP EP98910991A patent/EP0972530A4/en not_active Withdrawn
- 1998-03-25 CN CNB988036614A patent/CN1286535C/zh not_active Expired - Fee Related
- 1998-03-25 ID IDW991180A patent/ID22902A/id unknown
- 1998-03-25 TW TW087104518A patent/TW514537B/zh not_active IP Right Cessation
- 1998-03-25 CA CA002284619A patent/CA2284619A1/en not_active Abandoned
-
2003
- 2003-06-11 US US10/458,297 patent/US7056507B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0447984A1 (en) * | 1990-03-20 | 1991-09-25 | Abbott Laboratories | Hyperimmune globulin against hepatitis C virus and method for making same |
JPH0640926A (ja) * | 1992-07-24 | 1994-02-15 | Chemo Sero Therapeut Res Inst | C型肝炎ウイルスの除去方法 |
RU2095815C1 (ru) * | 1994-12-22 | 1997-11-10 | Леонид Николаевич Падюков | Способ получения иммуносорбента для диагностики вирусного гепатита с |
Non-Patent Citations (1)
Title |
---|
SAELBERG M., ET AL.: "PASSIVE ADSORPTION OF IMMUNOLOGICALLY ACTIVE AND INACTIVE SYNTHETICPEPTIDES TO POLYSTYRENE IS INFLUENCED BY THE PROPORTION OF NON- POLAR RESIDUES IN THE PEPTIDE.", IMMUNOLOGY LETTERS., ELSEVIER BV, NL, vol. 46., no. 01/02., 1 January 1995 (1995-01-01), NL, pages 25 - 30., XP002914398, ISSN: 0165-2478, DOI: 10.1016/0165-2478(95)00010-3 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003088381A (ja) * | 2001-09-18 | 2003-03-25 | Kanegafuchi Chem Ind Co Ltd | 新規ペプチド、生産方法、新規吸着体、吸着器および吸着方法 |
WO2003025011A1 (fr) * | 2001-09-18 | 2003-03-27 | Kaneka Corporation | Peptide, adsorbant, unite et methode d'adsorption |
US7153945B2 (en) | 2001-09-18 | 2006-12-26 | Kaneka Corporation | Peptide, novel adsorbent, adsorption unit and adsorption method |
JP4685294B2 (ja) * | 2001-09-18 | 2011-05-18 | 株式会社カネカ | 新規ペプチド、生産方法、新規吸着体、吸着器および吸着方法 |
WO2008016221A1 (en) | 2006-06-27 | 2008-02-07 | Korea Research Institute Of Bioscience And Biotechnology | Cysteine-tagged staphylococcal protein g variant |
JP2009542203A (ja) * | 2006-06-27 | 2009-12-03 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | システインタグ付きブドウ球菌タンパク質g変異体 |
US8541005B2 (en) | 2006-06-27 | 2013-09-24 | Korea Research Institute Of Bioscience And Biotechnology | Cysteine-tagged streptococcal protein G variant |
CN101185878B (zh) * | 2006-11-17 | 2010-05-26 | 广州康盛生物科技有限公司 | 一种用于去除致病抗体及其复合物的蛋白a免疫吸附材料及其合成方法和应用 |
CN103933947A (zh) * | 2014-04-10 | 2014-07-23 | 大连理工大学 | 用于清除类风湿因子的血液净化材料及其制备方法 |
CN103933947B (zh) * | 2014-04-10 | 2015-10-14 | 大连理工大学 | 用于清除类风湿因子的血液净化材料及其制备方法 |
US20180039170A1 (en) * | 2015-02-27 | 2018-02-08 | Canon Kabushiki Kaisha | Nanonimprint liquid material, method for manufacturing nanoimprint liquid material, method for manufacturing cured product pattern, method for manufacturing optical component, and method for manufacturing circuit board |
Also Published As
Publication number | Publication date |
---|---|
CN1251048A (zh) | 2000-04-19 |
CN1286535C (zh) | 2006-11-29 |
US7056507B2 (en) | 2006-06-06 |
US6600014B2 (en) | 2003-07-29 |
CA2284619A1 (en) | 1998-10-01 |
EP0972530A1 (en) | 2000-01-19 |
TW514537B (en) | 2002-12-21 |
US20040006214A1 (en) | 2004-01-08 |
KR20010005686A (ko) | 2001-01-15 |
KR20060015703A (ko) | 2006-02-17 |
EP0972530A4 (en) | 2003-01-29 |
US20030044769A1 (en) | 2003-03-06 |
ID22902A (id) | 1999-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998042392A1 (fr) | Adsorbant destine a eliminer le virus de l'hepatite c, adsorbeur et methode d'adsorption | |
JP4685294B2 (ja) | 新規ペプチド、生産方法、新規吸着体、吸着器および吸着方法 | |
JP3908278B2 (ja) | 免疫グロブリンおよびその複合体の吸着材、吸着方法、および吸着装置 | |
JP3955379B2 (ja) | C型肝炎ウイルス除去用吸着材、吸着装置及び吸着方法 | |
JP4541490B2 (ja) | 拡張型心筋症用吸着体 | |
JP3329868B2 (ja) | ペプチドおよびこれを担体上に固定化してなる吸着剤 | |
JPH0436300A (ja) | 変性ldlの吸着体およびそれを用いる変性ldlの除去装置 | |
JP3357139B2 (ja) | 抗デオキシリボ核酸抗体の吸着剤 | |
WO2012001142A1 (en) | Improved antibody binding affinity ligands | |
JPH06263795A (ja) | ペプチドおよびこれを担体上に固定化してなる吸着剤 | |
JPH01315338A (ja) | 低比重リポ蛋白質吸着材 | |
JPH0720991B2 (ja) | 新規なペプチドおよびその用途 | |
JP2006063024A (ja) | 糖化最終生成物に親和性を有するペプチド、およびそれを用いた吸着体 | |
JPH0544960B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98803661.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN ID KR SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019997008754 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2284619 Country of ref document: CA Ref document number: 2284619 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998910991 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09380644 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998910991 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997008754 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997008754 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998910991 Country of ref document: EP |